- Home
- WMB vs BMY Comparison
WMB vs BMY Comparison
Compare WMB & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WMB | BMY |
|---|---|---|
| Founded | 1908 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.6B | 113.5B |
| IPO Year | 2002 | 2006 |
Fundamental Metrics
Financial Performance| Metric | WMB | BMY |
|---|---|---|
| Price | $70.87 | $67.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 15 |
| Target Price | ★ $77.41 | $61.73 |
| AVG Volume (30 Days) | 6.0M | ★ 11.8M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | 2.86% | ★ 4.38% |
| EPS Growth | 17.58 | ★ 178.46 |
| EPS | 1.38 | ★ 2.93 |
| Revenue | $11,950,000,000.00 | ★ $48,194,000,000.00 |
| Revenue This Year | $6.97 | N/A |
| Revenue Next Year | $9.85 | N/A |
| P/E Ratio | $52.09 | ★ $22.37 |
| Revenue Growth | ★ 13.78 | N/A |
| 52 Week Low | $56.09 | $42.52 |
| 52 Week High | $80.08 | $68.64 |
Technical Indicators
Market Signals| Indicator | WMB | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 63.92 |
| Support Level | $69.47 | $56.46 |
| Resistance Level | $75.75 | $68.10 |
| Average True Range (ATR) | 2.06 | 1.59 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 30.46 | 75.62 |
Price Performance
Historical ComparisonAbout WMB Williams Companies Inc. (The)
Williams operates the Transco pipeline, which connects the Gulf Coast to the Northeast United States. It has additional natural gas transmission pipelines connecting the Rockies to the Pacific Northwest and midcontinent. At the field level, it operates substantial gathering and processing assets in Appalachia and other basins. The company has also struck several power supply agreements.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.